Brii Biosciences (HKSE:02137) Additional Paid-In Capital : HK$0.00 Mil(As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Brii Biosciences Additional Paid-In Capital?

Brii Biosciences's quarterly additional paid-in capital increased from Dec. 2022 (HK$0.00 Mil) to Jun. 2023 (HK$10,232.72 Mil) but then stayed the same from Jun. 2023 (HK$10,232.72 Mil) to Dec. 2023 (HK$0.00 Mil).

Brii Biosciences Additional Paid-In Capital Historical Data

The historical data trend for Brii Biosciences's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Brii Biosciences Additional Paid-In Capital Chart

Brii Biosciences Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Brii Biosciences Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Additional Paid-In Capital	Get a 7-Day Free Trial				-	-	-	10,232.72	-

Brii Biosciences Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Brii Biosciences Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Brii Biosciences's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Brii Biosciences (HKSE:02137) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Brii Biosciences Ltd (HKSE:02137) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

BRIBF:USA 7SS:Germany

Address

No. 1 North Yongtaizhuang Road, 3rd Floor, Building 7, Zhongguancun Dongsheng, International Science Park, Haidian District, Beijing, CHN, 100192

Website

https://www.briibio.com

Brii Biosciences Ltd is a biotechnology company based in China and the United States. It is committed towards developing advancing therapies for infectious diseases, such as HBV, HIV, MDR/XDR gram-negative infections, and other illnesses, such as the CNS diseases, which have public health burdens in China and worldwide. The company's pipeline of products includes more than 10 product candidates that focus on infectious diseases and mental illnesses.

Executives

Hong Zhi	2101 Beneficial owner
Xyxy Holdings Ltd.	2201 Interest of corporation controlled by you
Booming Passion Limited	2101 Beneficial owner
Boyu Capital Fund Iii, L.p.	2201 Interest of corporation controlled by you
Boyu Capital General Partner Iii, L.p.	2201 Interest of corporation controlled by you
Boyu Capital General Partner Iii, Ltd	2201 Interest of corporation controlled by you
Tong Xiaomeng	2201 Interest of corporation controlled by you
Boyu Group, Llc	2201 Interest of corporation controlled by you
Boyu Capital Group Holdings Ltd	2201 Interest of corporation controlled by you
Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
Invesco Advisers, Inc.	2102 Investment manager
Ma Yun	2201 Interest of corporation controlled by you
Yunfeng Investment Iii, Ltd.	2201 Interest of corporation controlled by you
Yunfeng Fund Iii, L.p.	2201 Interest of corporation controlled by you
Yf Bright Insight Limited	2101 Beneficial owner

Brii Biosciences (HKSE:02137) Headlines

No Headlines